NYSE:JNJPharmaceuticals
Johnson And Johnson Bladder Cancer Data Adds Interest To Valuation Story
Johnson & Johnson (NYSE:JNJ) reported strong Phase 1 results for its intravesical erdafitinib drug releasing system in non muscle invasive bladder cancer.
The program showed high response rates, durable remission, and an encouraging safety profile in intermediate and high risk patients.
The data support moving the Erda iDRS program into late stage development as a localized treatment approach.
For investors watching NYSE:JNJ, this update adds a fresh piece of information to the company...